Silexion Restores Nasdaq Compliance After Strategic Moves

Silexion Therapeutics ( (SLXN) ) has issued an announcement.

On September 23, 2025, Silexion Therapeutics Corp. received confirmation from Nasdaq that it had restored compliance with the shareholders’ equity and minimum bid price requirements necessary for continued listing on the Nasdaq Capital Market. This follows a series of strategic financial moves, including a 1-for-15 reverse share split and financing transactions that increased the company’s shareholders’ equity. The company will be under a mandatory panel monitor until September 23, 2026, to ensure ongoing compliance.

The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics Corp. operates within the biotechnology industry, focusing on developing innovative therapeutic solutions. The company is listed on the Nasdaq Capital Market and is committed to maintaining compliance with Nasdaq’s listing requirements.

Average Trading Volume: 404,051

Technical Sentiment Signal: Sell

Current Market Cap: $8.19M

For detailed information about SLXN stock, go to TipRanks’ Stock Analysis page.